Hoffmann-La Roche Inc.;VIB vzw;Life Sciences Research Partners vzw
发明人:
Peter Carmeliet,Sanne Lysbet de Haas,Diether Lambrechts,Stefan Scherer
申请号：
US15354454
公开号：
US20170066822A1
申请日:
2016.11.17
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.
